Terumo Medical Corporation Celebrates Opening of New Manufacturing Facility at Its Puerto Rico Location
– Meets growing global demand for Terumo’s ANGIO-SEAL® Vascular Closure Device
– $45 million investment will result in approximately 180 additional jobs and regional economic growth
– Strengthens Terumo’s commitment to healthcare providers and the patients they care for across the globe
SOMERSET, NJ and CAGUAS, PR – August 20, 2025 – Terumo Medical Corporation (TMC) is pleased to announce the official opening of its new, 64,000-square-foot manufacturing facility at the company’s Caguas, Puerto Rico, location.
The new facility is designed to meet increasing global demand for Terumo’s ANGIO-SEAL® Vascular Closure Device (VCD), manufactured exclusively in Puerto Rico. A long-time leader in the global market, Terumo’s ANGIO-SEAL Device provides active closure for reliable and rapid hemostasis in patients who have undergone angiographic or interventional procedures. The device – which has been used by healthcare professionals to treat more than 10 million patients worldwide – has also proven to accelerate patient mobility and enable same-day discharge, or the potential for patients to be home for recovery soon after their procedures.
“The completion of our new, expanded facility is an important milestone for Terumo, our associates in Caguas and, most importantly, our customers and their patients who rely on the ANGIO-SEAL Device,” said Jim Rushworth, President and Chief Operating Officer, Terumo Medical Corporation. “By expanding our production capacity in Puerto Rico, we stand ready to meet growing demand in a highly competitive market, while we strive to achieve better outcomes for patients across the globe.”
The Caguas location currently employs 375 associates, with approximately 180 jobs to be added in the future. An existing, 22,000-square-foot building will continue to be utilized to support related production and administrative needs, with plans for future renovations.
“The construction of this new facility – nearly triple the size of the old one – is a testament to the commitment and dedication of our associates, and builds upon our mission to contribute to society through healthcare,” said Rafael Benitez, Senior Director and Site Leader, Terumo Puerto Rico. “It is a meaningful accomplishment – one that will benefit our company, our customers and, from an economic and community partner standpoint, the island of Puerto Rico.”
About Terumo Medical Corporation
Terumo Medical Corporation (TMC), a subsidiary of Terumo Corporation, was founded in 1972 as the United States expansion of our larger Tokyo-based parent. For over 50 years, TMC has continued the Terumo mission of “Contributing to Society through Healthcare” by offering the best possible solutions to healthcare providers and the patients they serve. A global medical device company with manufacturing facilities in Elkton, MD and Caguas, Puerto Rico, TMC provides products and services across four divisions. They include: 1) Terumo Interventional Systems (TIS), a market leader in minimally invasive entry site management, lesion access, and therapeutic intervention for cardiology, peripheral arterial disease, embolotherapy and interventional oncology; 2) Terumo Health Outcomes (THO), which provides healthcare systems with solutions designed to reduce care variation, improve quality metrics, minimize costs, and maximize revenue; 3) Terumo Medical Care Solutions (TMCS), which provides devices for injection and infusion therapy; and 4) the Pharmaceutical Solutions Division (PSD), which develops drug delivery devices.
About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for over 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large. More information can be found at www.terumo.com.d third parties.